BioCentury | Nov 5, 2020

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

Although VelosBio appeared to be heading down the path to an IPO, the oncology company has instead accepted a $2.8 billion takeout offer from Merck now that the biotech’s antibody-drug conjugate has shown signs of...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
BioCentury | Oct 31, 2020

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

Q32 raises $60M series B round, starts first clinical trialImmunology company Q32 Bio Inc. raised $60 million in a series B round led by OrbiMed Advisors and Acorn Bioventures, with participation from Osage University Partners, Atlas...
BioCentury | Jul 8, 2020

VelosBio jumps on megaround bandwagon with $137M series B

With its $137 million series B round Wednesday, VelosBio became the 50th biotech this year to raise a venture round topping the $100 million mark (see "Venture Megarounds Tracking to New Record” ). It is...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | May 7, 2019
Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

...fibrillary acidic protein (GFAP) in astrocytes. Down-regulated genes included synaptosomal-associated protein 25 (SNAP25) in oligodendrocytes, RAR-related orphan receptor...
...protein (GFAP) Leucine rich repeat and Ig domain containing 1 (LINGO1) Potassium voltage-gated channel interacting protein 1 (KCNIP1) RAR-related orphan receptor...
BioCentury | Apr 11, 2019
Company News

WuXi Biologics to manufacture NBE’s ADC for clinical trials

WuXi Biologics will manufacture NBE-Therapeutics’ lead antibody-drug conjugate, NBE-002, for use in clinical trials worldwide. NBE-Therapeutics AG (Basel, Switzerland) plans to begin trials of the ADC in mid-2020. NBE-Therapeutics declined to disclose details. WuXi Biologics...
BioCentury | Mar 26, 2019
Distillery Therapeutics

The short-chain fatty acid pentanoate for MS

...expression of the anti-inflammatory cytokine IL-10 and decreased expression of pro-inflammatory genes, including IL-21 and RAR-related orphan receptor...
BioCentury | Mar 14, 2019
Company News

GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the...
BioCentury | Feb 15, 2019
Company News

India's Glenmark spinning out innovative assets into U.S. unit

...factor receptor superfamily member 4; PTGES (mPGES-1) - Microsomal prostaglandin E synthase-1; RORγT (RORγ2) - RAR-related orphan receptor...
Items per page:
1 - 10 of 123